Longeveron (LGVN) Stock Forecast, Price Target & Predictions
LGVN Stock Forecast
Longeveron stock forecast is as follows: an average price target of $10.00 (represents a 506.06% upside from LGVN’s last price of $1.65) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
LGVN Price Target
LGVN Analyst Ratings
Buy
Longeveron Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 29, 2024 | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $3.44 | 190.70% | 506.06% |
Longeveron Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $10.00 |
Last Closing Price | $1.65 | $1.65 | $1.65 |
Upside/Downside | -100.00% | -100.00% | 506.06% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 27, 2024 | Maxim Group | Buy | Buy | Hold |
Jul 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Longeveron Financial Forecast
Longeveron Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $150.00K | $217.00K | $279.00K | $121.00K | $265.00K | $466.00K | $370.00K | $209.00K |
Avg Forecast | $1.23M | $1.18M | $1.09M | $1.05M | $839.82K | $796.37K | $742.80K | $666.02K | $578.66K | $395.50K | $500.00K | $60.00K | $210.00K | $400.00K | $400.00K | $300.00K | $400.00K | $200.00K | $200.00K | $250.00K | $265.00K |
High Forecast | $1.63M | $1.57M | $1.45M | $1.39M | $1.11M | $1.06M | $984.58K | $872.39K | $745.24K | $524.23K | $662.75K | $79.53K | $290.00K | $530.20K | $530.20K | $397.65K | $530.20K | $200.00K | $200.00K | $250.00K | $265.00K |
Low Forecast | $674.61K | $649.62K | $599.65K | $574.66K | $460.91K | $437.06K | $407.66K | $375.22K | $280.56K | $217.06K | $274.41K | $32.93K | $130.00K | $219.53K | $219.53K | $164.65K | $219.53K | $200.00K | $200.00K | $250.00K | $265.00K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.54% | 0.93% | 0.30% | 1.32% | 2.33% | 1.48% | 0.79% |
Forecast
Longeveron EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.16M | $-5.71M | $-4.72M | $-4.56M | $-5.00M | $-4.00M | $-3.21M | $-8.46M |
Avg Forecast | $-960.92K | $-925.34K | $-854.15K | $-818.57K | $-656.53K | $-622.56K | $-580.69K | $-520.66K | $-452.37K | $-309.18K | $-390.88K | $-46.91K | $-164.17K | $-312.70K | $-312.70K | $-234.53K | $-312.70K | $-156.35K | $-156.35K | $-4.08M | $-207.16K |
High Forecast | $-527.37K | $-507.84K | $-468.77K | $-449.24K | $-360.31K | $-341.67K | $-318.69K | $-293.33K | $-219.33K | $-169.68K | $-214.52K | $-25.74K | $-101.63K | $-171.62K | $-171.62K | $-128.71K | $-171.62K | $-156.35K | $-156.35K | $-3.26M | $-207.16K |
Low Forecast | $-1.27M | $-1.23M | $-1.13M | $-1.09M | $-870.23K | $-825.20K | $-769.70K | $-681.99K | $-582.59K | $-409.82K | $-518.10K | $-62.17K | $-226.71K | $-414.48K | $-414.48K | $-310.86K | $-414.48K | $-156.35K | $-156.35K | $-4.89M | $-207.16K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.50% | 18.27% | 20.11% | 14.57% | 32.01% | 25.56% | 0.79% | 40.85% |
Forecast
Longeveron Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.90M | $-5.63M | $-4.58M | $-3.77M | $-5.30M | $-7.03M | $-3.63M | $-8.92M |
Avg Forecast | - | - | - | - | $-5.25M | $-4.97M | $-4.84M | $-5.18M | $-5.04M | $-5.31M | $-15.26M | $-27.32M | $-29.07M | $-30.66M | $-33.62M | $-29.07M | $-27.26M | $-14.32M | $-14.76M | $-4.31M | $-16.27M |
High Forecast | - | - | - | - | $-2.17M | $-2.06M | $-2.00M | $-4.60M | $-4.62M | $-2.20M | $-6.31M | $-11.30M | $-26.30M | $-12.68M | $-13.90M | $-12.02M | $-11.27M | $-14.32M | $-14.76M | $-3.45M | $-16.27M |
Low Forecast | - | - | - | - | $-7.47M | $-7.08M | $-6.89M | $-5.75M | $-5.60M | $-7.56M | $-21.72M | $-38.89M | $-31.84M | $-43.64M | $-47.84M | $-41.37M | $-38.79M | $-14.32M | $-14.76M | $-5.17M | $-16.27M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.19% | 0.17% | 0.16% | 0.14% | 0.37% | 0.48% | 0.84% | 0.55% |
Forecast
Longeveron SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.37M | $3.52M | $2.01M | $1.92M | $2.32M | $2.66M | $2.27M | $5.39M |
Avg Forecast | $8.39M | $8.08M | $7.46M | $7.15M | $5.73M | $5.43M | $5.07M | $4.55M | $3.95M | $2.70M | $3.41M | $409.46K | $1.43M | $2.73M | $2.73M | $2.05M | $2.73M | $1.36M | $1.36M | $1.71M | $1.81M |
High Forecast | $11.12M | $10.71M | $9.88M | $9.47M | $7.60M | $7.20M | $6.72M | $5.95M | $5.09M | $3.58M | $4.52M | $542.73K | $1.98M | $3.62M | $3.62M | $2.71M | $3.62M | $1.36M | $1.36M | $1.71M | $1.81M |
Low Forecast | $4.60M | $4.43M | $4.09M | $3.92M | $3.15M | $2.98M | $2.78M | $2.56M | $1.91M | $1.48M | $1.87M | $224.72K | $887.16K | $1.50M | $1.50M | $1.12M | $1.50M | $1.36M | $1.36M | $1.71M | $1.81M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.24% | 1.29% | 0.98% | 0.70% | 1.70% | 1.95% | 1.33% | 2.98% |
Forecast
Longeveron EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.28 | $-0.27 | $-0.22 | $-0.18 | $-0.25 | $-0.34 | $-0.17 | $-0.45 |
Avg Forecast | - | - | - | - | $-0.39 | $-0.36 | $-0.35 | $-0.38 | $-0.37 | $-0.39 | $-1.12 | $-2.00 | $-2.13 | $-2.25 | $-2.47 | $-2.13 | $-2.00 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
High Forecast | - | - | - | - | $-0.16 | $-0.15 | $-0.15 | $-0.34 | $-0.34 | $-0.16 | $-0.46 | $-0.83 | $-1.93 | $-0.93 | $-1.02 | $-0.88 | $-0.83 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
Low Forecast | - | - | - | - | $-0.55 | $-0.52 | $-0.51 | $-0.42 | $-0.41 | $-0.56 | $-1.59 | $-2.85 | $-2.34 | $-3.20 | $-3.51 | $-3.04 | $-2.85 | $-2.20 | $-2.27 | $-2.25 | $-2.50 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.12% | 0.11% | 0.10% | 0.09% | 0.11% | 0.15% | 0.08% | 0.18% |
Forecast
Longeveron Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
KPRX | Kiora Pharmaceuticals | $3.49 | $120.00 | 3338.40% | Buy |
KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
LGVN | Longeveron | $1.78 | $10.00 | 461.80% | Buy |
CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |